1 |
W. Johnson Jr., W. F. Bergfeld, D. V. Belsito, R. A. Hill, C. D. Klaassen, D. Liebler, J. G. Marks Jr., R. C Shank, T. J. Slaga, P. W. Snyder, and F. A. Andersen, Safety Assessment of 1, 2-Glycols as Used in Cosmetics. Int. J. Toxicol., 31(5 Suppl), 147S (2012).
DOI
|
2 |
E. Lee, S. An, S.-A. Cho, Y. Yun, J. Han, Y. K. Hwang, H. K. Kim, and T. R. Lee, The Influence of Alkane Chain Length on the Skin Irritation Potential of 1, 2-Alkanediols, Int. J. Cosmet. Sci., 33(5), 421 (2011).
DOI
|
3 |
S. B. Levy, A. M. Dulichan, and M. Helman, Safety of a Preservative System containing 1, 2-Hexanediol and Caprylyl glycol, Cutan. Ocu.l Toxicol., 28(1), 23 (2009).
DOI
|
4 |
S. -E. Lee, T. M. Jo, H. -Y. Lee, J. Lee, and K. -H. Jung, -Galactosidasecatalyzed Synthesis of Galactosyl Chlorphenesin and its Characterization, Appl. Biochem. Biotechnol., 171(6), 1299 (2013).
DOI
|
5 |
Y. -O. Kim and K. -H. Jung, Enzymatic Synthesis of 1, 2-Hexanediol Galactoside by Whole cells of -Galactosidasecontaining Recombinant Escherichia coli. J. Life Sci., 26(5), 608 (2016).
DOI
|
6 |
S. -E. Lee, H. -Y. Lee, and K. -H. Jung, Production of Chlorphenesin Galactoside by Whole Cells of -Galactosidasecontaining Escherichia coli, J. Microbiol. Biotechnol., 23(6), 826 (2013).
DOI
|
7 |
H. -Y. Lee and K. -H. Jung, Enzymatic Synthesis of 2-Phenoxyethanol Galactoside by Whole Cells of -Galactosidasecontaining Escherichia coli, J. Microbiol. Biotechnol., 24(9), 1254 (2014).
DOI
|
8 |
K. -H. Jung and H. -Y. Lee, Escherichia coli -Galactosidase-catalyzed Synthesis of 2-Phenoxyethanol Galactoside and its Characterization, Bioprocess Biosyst. Eng., 38(2), 365 (2015).
DOI
|
9 |
G. D. Benjamin and M. A. Robinson, Drug Delivery Systems based on Sugar-macromolecule Conjugates, Curr. Opin. Drug Discov. Devel., 5(2), 279 (2002).
|
10 |
J. Huang, F. Gao, X. Tang, J. Yu, D. Wang, S. Liu, and Y. Li, Liver-targeting Doxorubicin-conjugated Polymeric Prodrug with pH-Triggered Drug Release Profile, Polym. Int., 59(10), 1390 (2010).
DOI
|
11 |
N. Bridiau, S. Taboubi, N. Marzouki, M. D. Legoy, and T. Maugard, -Galactosidase Catalyzed Selective Galactosylation of Aromatic Compounds, Biotechnol. Prog., 22(1), 326 (2006).
DOI
|
12 |
D. Melisi, A. Curcio, E. Luongo, E. Morelli, and M. G. Rimoli, D-Galactose as a Vector for Prodrug Design, Curr. Top. Med. Chem., 11(18), 2288 (2011).
DOI
|
13 |
L. F. Tietze and K. Schmuck, Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT, Curr. Pharm. Design, 17(32), 3527 (2011).
DOI
|
14 |
L. Q. Yan, N. Li, and M. H. Zong, First Enzymatic Galactosylation of Acyclic Nucleoside Drugs by -Galactosidase: Synthesis of Water-soluble -DGalactosidic Prodrugs, Biotechnol. Bioprocess Eng., 19(4), 586 (2014).
DOI
|
15 |
K. -H. Jung, Enhanced Enzyme Activities of Inclusion Bodies of Recombinant -Galactosidase via the Addition of Inducer Analog after L-Arabinose Induction in the araBAD Promoter System of Escherichia coli, J. Microbiol. Biotechnol., 18(3), 434 (2008).
|
16 |
K. -H. Jung, J. -H. Yeon, S. -K. Moon, and J. -H. Choi, Methyl -DGlucopyranoside Enhances the Enzymatic Activity of Recombinant -Galactosidase Inclusion Bodies in the araBAD Promoter System of Escherichia coli. J. Ind. Microbiol. Biotechnol., 35(7), 695 (2008).
DOI
|
17 |
C. Scheckermann, F. Wagner, and L. Fischer, Galactosylation of Antibiotics using the -Galactosidase from Aspergillus oryae, Enzyme Microb. Technol., 20(8), 629 (1997).
DOI
|